Boehringer Ingelheim Launches Enrolment in COPD Trial Program

Boehringer Ingelheim has announced the enrolment of its first patient for a new phase III trial of an investigational chronic obstructive pulmonary disease therapy.

German drug major Boehringer Ingelheim has initiated patient enrolment in its TOviTO Phase III clinical trial program. It will investigate tiotropium plus olodaterol in a once-daily fixed-dose combination for the treatment of chronic obstructive pulmonary disease (COPD).

Boehringer Ingelheim has decided to move the once-daily fixed-dose combination of tiotropium plus olodaterol into the TOviTO Phase III trial program on the back of promising olodaterol Phase III trial results, which will be published in the near future.

The TOviTO program includes several trials that will provide important evidence to support olodaterol's potential to improve patients' lives beyond optimal bronchodilation.